Table 1 Baseline characteristics of the intention-to-treat population
From: Loxapine to control agitation during weaning from mechanical ventilation
Loxapine (n = 48) | Placebo (n = 39) | p Value | |
|---|---|---|---|
Age, years (SD) | 59.6 (15.6) | 51 (17.7) | 0.02 |
Male sex, n (%) | 35 (74.5) | 31 (79.5) | 0.6 |
SAPS II score (SD) | 48.2 (17.2) | 53.7 (17.9) | 0.15 |
SOFA score [IQR] | 9 [5–12] | 9 [7–11] | 0.8 |
Alcohol consumption, n (%) | 13 (28) | 17 (44) | 0.12 |
Toxic drug abuse, n (%) | 5 (11) | 6 (15) | 0.54 |
Psychoactive drug use, n (%) | 8 (17) | 10 (26) | 0.33 |
Indication for MV | |||
Acute respiratory failure, n (%) | 23 (49) | 16 (41) | 0.46 |
Shock, n (%) | 12 (25) | 9 (23) | 0.48 |
Coma, n (%) | 8 (17) | 9 (23) | 0.48 |
Co-morbid conditions | |||
COPD, n (%) | 5 (11) | 4 (10) | 1.0 |
Congestive heart disease, n (%) | 6 (13) | 4 (10) | 1.0 |
Chronic renal failure, n (%) | 2 (4) | 0 (0) | 0.5 |
Hepatic disease, n (%) | 1 (2) | 1 (3) | 1.0 |
Duration of MV before randomisation, days [IQR] | 5 [3–7] | 6 [5–8] | 0.06 |
Cumulative amount of sedative drugs in the previous 24 h | |||
Midazolam, mg | 114 [40–230] | 120 [57–341] | 0.5 |
Fentanyl, μg | 2150 [1731–4000] | 2700 [2550–4300] | 0.6 |
Sufentanil, μg | 247.5 [107–333.75] | 270 [130–638.75] | 0.2 |
Propofol, mg | 1440 [750–2550] | 1520 [1085–2400] | 0.3 |